Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.

摘要: Purpose To determine the frequency and clinical significance of epidermal growth factor receptor (EGFR) mutations in patients with potentially curable stage III non–small-cell lung cancer (NSCLC) who are eligible for definitive chemoradiotherapy (CRT). Patients Methods Between January 2001 December 2010, we analyzed EGFR mutational status consecutive NSCLC were treated by CRT. The response rate, relapse-free survival, 2-year initial relapse sites, overall survival investigated. Results A total 528 received CRT at our hospital during study period. Of these, 274 diagnosed as having nonsquamous NSCLC. Sufficient specimens analyses could be obtained from 198 these patients. proportion activating was 17%. In addition to well-known characteristics carrying (female, adenocarcinoma, never/light smoker), cases smaller primary lesions (T1/2) found higher than those wild-type EGFR. showed similar rates compared Local relapses site occurred significantly less frequently mutation (4% vs 21%; P =.045). longer local control (adjusted hazard ratio 0.49; =.043). After disease progression, a majority tyrosine kinase inhibitors (62%), postprogression Conclusions Our is first show radiosensitive biology EGFR-mutated tumors curative intent. This finding serve credible baseline estimate population